Company: PCRX
Filing Date: 2025-04-18
Form Type: DEFA14A
Source: 0001396814-25-000053
Chunk: 1

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-18
Form: DEFA14A
Chunk 1
---
 value. The share repurchase authorization expires at the end of December 2026.

•

#### Commitment to Efficiency and Margin Expansion
. The Pacira Board and management team are committed to enhancing the company’s operational efficiency and expect to prioritize opportunities to drive margin expansion at the pre-tax net income level to further enhance value for shareholders.

This increased share repurchase authorization underscores the Board’s confidence in Pacira’s growth strategy and our commitment to delivering value to shareholders.

We have already made significant progress on our value creation plan and remain focused and disciplined as we grow and accelerate our transformation into an innovative biopharmaceutical company, leading in musculoskeletal pain and adjacencies.

You can find the full release here.

#### Forward-Looking Statements
Any statements in this document about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: Pacira’s board of directors, ‘5x30’, Pacira’s growth and business strategy; Pacira’s future outlook, Pacira’s intellectual property and patent terms, Pacira’s growth and future operating results and trends, Pacira’s strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, including Pacira’s plans with respect to the repayment of Pacira’s indebtedness, anticipated product portfolio, development programs, development of products, strategic alliances and other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. Pacira cannot assure you that its estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: the failure to realize the anticipated benefits and synergies from the acquisition of GQ Bio Therapeutics GmbH; risks associated with acquisitions, such as the

risk that the acquired businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected